
Opinion|Videos|August 21, 2024
First-Line Immune Checkpoint Inhibitor for Favorable-Risk Metastatic Renal Cell Carcinoma
Key opinion leaders present an overview of first-line immune checkpoint inhibitor combination regimens specifically tailored for patients with favorable-risk metastatic renal cell carcinoma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5






































